FDC Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: FDC Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $11.8M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

FDC Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $11.8M Trade | TransData Nexus

FDC Limited

Indian Pharmaceutical Exporter · Antibiotics Specialist · $11.8M Total Trade · DGFT Verified

FDC Limited is an Indian pharmaceutical exporter with a total trade value of $11.8M across 3 products in 2 therapeutic categories. Based on 369 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ofloxacin ($5.5M), Ciprofloxacin ($4.8M), Gentamicin ($1.6M).

FDC Limited — Export Portfolio & Destination Treemap

FDC Limited pharmaceutical export portfolio — 3 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is FDC Limited? — Company Overview & Market Position

FDC Limited, established in 1936, is a prominent Indian pharmaceutical company specializing in the manufacturing and marketing of finished pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company was incorporated as a private limited entity in 1940 and later transitioned to a public limited company, listed on the Bombay and National Stock Exchanges of India in 1996. Headquartered in Mumbai, Maharashtra, FDC Limited operates with a workforce of approximately 6,857 employees. The company's diverse product portfolio includes tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and pediatric-friendly solutions, catering to various therapeutic segments such as anti-infectives, gastrointestinal, ophthalmology, vitamins, minerals, dietary supplements, cardiovascular and anti-diabetic therapies, respiratory care, gynecology, dermatology, and analgesics. FDC Limited markets its products under several well-known brands, including Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Vitcofol, Ziglim, Ziglim-M, Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Electral, and Enerzal.

What Does FDC Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ofloxacin$5.5M 2

Product Portfolio — Top 3 by Export Value

FDC Limited exports 3 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ofloxacin	Advanced Antibiotics	$5.5M	110	1.9%	10
2	Ciprofloxacin	Antibiotics	$4.8M	99	1.6%	11
3	Gentamicin	Antibiotics	$1.6M	160	3.1%	7

FDC Limited exports 3 pharmaceutical products across 2 therapeutic categories with a total export value of $11.8M. The top category is Antibiotics (53.6% of portfolio), followed by Advanced Antibiotics (46.4%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

FDC Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

FDC Limited operates multiple manufacturing facilities across India, strategically located to enhance production capabilities and meet global demand. These facilities are situated in Roha, Waluj, and Sinnar in Maharashtra; Verna in Goa; and Baddi in Himachal Pradesh. The Roha plant specializes in the production of pharmaceutical dosage forms, food products, and bulk drugs for the anti-rheumatic, anti-asthmatic, ophthalmic, and ENT segments. FDC Limited's manufacturing plants are accredited by various international regulatory bodies, including the US FDA, UK MHRA, MCC RSA, and the UAE, ensuring compliance with global quality standards.

3Key Leadership

FDC Limited's leadership team comprises experienced professionals dedicated to steering the company towards sustained growth and innovation. The key executives include:

Ameya Ashok Chandavarkar – Chief Executive Officer of International Business and Executive Director.

Dr. Nandan Mohan Chandavarkar – Joint Managing Director and Executive Director.

Mohan Anand Chandavarkar – Business Head, Managing Director, and Director.

Vishal Shah – Chief Financial Officer.

Shashank Vyapari – Vice President of Technical and Operations.

Sanjay B. Jain – Vice President of Corporate Finance.

Varsharani Rajaram Katre C.S. – Legal Head, Compliance Officer, and Company Secretary.

Zafrullah Khan – Senior Vice President – Human Resources.

Mayank Tikkha – Senior Vice President – Business Development.

Shivaji S. Nalawade – Senior Vice President – Distribution.

This leadership team is instrumental in driving FDC Limited's strategic initiatives and maintaining its position as a leading player in the pharmaceutical industry.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does FDC Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

FDC Limited has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has achieved accreditations from the US FDA, UK MHRA, MCC RSA, and the UAE, among others, ensuring compliance with international quality standards. FDC Limited exports its products to approximately 50 countries, reflecting its global reach and adherence to stringent regulatory requirements. The company's manufacturing facilities are approved by various international regulatory bodies, including the US FDA, UK MHRA, MCC RSA, and the UAE, ensuring compliance with global quality standards. This extensive regulatory compliance underscores FDC Limited's commitment to delivering high-quality pharmaceutical products to markets worldwide.

2Emerging Markets

FDC Limited has strategically expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to international quality standards, as evidenced by its accreditations from the US FDA, UK MHRA, MCC RSA, and the UAE, facilitates its entry into these regions. By obtaining WHO prequalification, FDC Limited enhances its ability to supply essential medicines to these markets, thereby contributing to global health initiatives and expanding its market presence.

Geographic Strategy

FDC Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

FDC Limited's manufacturing facilities are registered with the US FDA, reflecting the company's commitment to meeting stringent regulatory standards. The company has filed multiple Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs), facilitating the approval of its generic pharmaceutical products in the United States. FDC Limited's facilities have undergone inspections by the US FDA, resulting in favorable outcomes that affirm the company's adherence to Good Manufacturing Practices (GMP). This regulatory compliance underscores FDC Limited's dedication to delivering high-quality pharmaceutical products to the US market.

2WHO & EU GMP

FDC Limited's manufacturing facilities are certified with WHO-GMP and EU GMP, demonstrating the company's commitment to maintaining high-quality manufacturing standards. These certifications enable FDC Limited to supply pharmaceutical products to international markets that require compliance with WHO and EU GMP guidelines. The company's adherence to these standards ensures the safety, efficacy, and quality of its products, reinforcing its reputation as a reliable pharmaceutical manufacturer.

3CDSCO & Indian Regulatory

FDC Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

FDC Limited operates in a competitive pharmaceutical industry, facing competition from both domestic and international companies. In the anti-infective segment, FDC Limited's top products include Ofloxacin, Ciprofloxacin, and Gentamicin, with export values of $5.5 million, $4.8 million, and $1.6 million, respectively. These products hold market shares of 1.9%, 1.6%, and 3.1%, respectively, indicating a strong presence in the market. The company's focus on high-quality formulations and adherence to international standards positions it favorably against competitors in overlapping categories.

2Key Differentiators

FDC Limited's key differentiators include its extensive product portfolio, which encompasses over 300 products across various therapeutic segments, and its strong presence in the oral rehydration solutions (ORS) and ophthalmic therapy markets. The company's manufacturing facilities are accredited by international regulatory bodies, including the US FDA, UK MHRA, MCC RSA, and the UAE, ensuring compliance with global quality standards.

TransData Nexus Research · DGFT export records, industry analysisMar 2026

Frequently Asked Questions — FDC Limited

How many pharmaceutical products does FDC Limited export from India?

FDC Limited exports 3 pharmaceutical products across 2 therapeutic categories. The top exports are Ofloxacin ($5.5M), Ciprofloxacin ($4.8M), Gentamicin ($1.6M). Total export value is $11.8M.

What is FDC Limited's total pharmaceutical export value?

FDC Limited's total pharmaceutical export value is $11.8M, based on 369 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does FDC Limited cover?

FDC Limited exports across 2 therapeutic categories. The largest are Antibiotics (53.6%, 2 products), Advanced Antibiotics (46.4%, 1 products).

Get Full FDC Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.